Aura Biosciences(US:AURA) Globenewswire·2025-11-13 12:00Core Insights - Aura Biosciences is focused on advancing its clinical trials for bel-sar, particularly in early choroidal melanoma and non-muscle invasive bladder cancer (NMIBC), with enrollment challenges being addressed and improved recently [2][5][6] Clinical Trials and Pipeline Developments - The Phase 3 CoMpass trial for early choroidal melanoma is the first registration-enabling trial in this indication, with approximately 90% of targeted clinical sites activated and enrollment expected to complete in 2026 [3][4][5] - The topline data readout for the 15-month primary endpoint of the CoMpass trial is anticipated in Q4 2027 [5] - The ongoing Phase 1b/2 trial for NMIBC is on track, with initial data expected in mid-2026, showcasing bel-sar's potential as a frontline therapy [2][11] - Recent immune profiling data from the Phase 1 trial indicate bel-sar's ability to convert 'cold' tumors to 'hot' tumors, enhancing its therapeutic profile [9][10] Financial Performance - As of September 30, 2025, the company reported cash and cash equivalents totaling $161.9 million, sufficient to fund operations into the first half of 2027 [16] - Research and development expenses increased to $22.2 million in Q3 2025 from $17.0 million in Q3 2024, primarily due to clinical trial costs [16] - The net loss for Q3 2025 was $26.1 million, compared to $21.0 million in Q3 2024, reflecting ongoing investment in clinical development [17]